Best health care companies in Menlo Park, CA

Intersect ENT Inc. (formerly Sinexus) is a medical device company pioneering novel therapies for Ear, Nose & Throat surgeons to utilize in providing improved treatment for their patients.

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.

Provider of on demand drug delivery platform intended to create a better experience for patients at a lower price. The company's prescription delivery service offers same-day delivery to the home or office at competitive pricing with traditional pharmacies as well as offers a mobile application for patients to get virtual consultations with pharmacists, enabling users to manage their prescriptions and deliveries from their preferred device.

Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both in variant detection and interpretation.

Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously - resulting in more potent and targeted treatments beyond a single target and function.

Grail develops a pan-cancer screening test designed to detect cancer early. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.

Strateos automates chemistry, biology, and tissue analysis into closed loop robotic labs that accelerate drug discovery programs. Through a combination of best-in-class robotics and control systems, advanced software for imaging and analytics, and remote cloud laboratories, we enable our pharmaceutical partners to more rapidly and efficiently discover new drug candidates. Born of a merger between Transcriptic and 3Scan, Strateos combines the strengths of those companies to amplify their impact and accelerate drug discovery. Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. 3Scan combined automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development. By expressing life science methods as data, infrastructure virtualization will become possible. "Science-as-a-Service" will power the next generation of discovery, driven by huge efficiencies of both time and money. Transcriptic was founded in 2012 to create a better way to get lab work done. Tired of spending endless hours at the bench pretending to be slow, error-prone robots, they set out to build a modern solution to the day-to-day process of wet lab biology. Drawing on deep computer science and electrical engineering backgrounds in addition to life science, Strateos was born: a meticulously optimized, technology-enabled remote lab. Using state-of-the-art automation and control technology, and an emphasis on user experience and usability, they are working on building a stark contrast to the long, complicated sales process, high prices, and slow turnarounds of traditional CROs. They are working hard to build a great company that can be a true partner for your lab for a long time, progressively enabling ever greater levels of productivity and efficiency. They are scientists building for scientists.

Adverum Biotechnologies, formerly Avalanche Biotechnologies, is a gene therapy company. The company focuses in discovering and developing medicines that can offer therapeutic benefit to patients dealing with chronic or debilitating disease. Adverum was formed after the merger of Avalanche Biotechnologies and Annapurna Therapeutics in May 2016.

Synthekine a biotechnology company focused on discovery and developing best in class cytokine therapeutics.

ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode's diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company's proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

BillionToOne is the developer of a patent-pending QCT molecular counter platform designed to accurately count DNA molecules to the single-count level.

CSBio provides high-quality custom peptides, cGMP peptides, automated peptide synthesizers and other instrumentation to the global biotech community.

Conor MedSystems develops innovative controlled vascular drug delivery technologies. They have initially focused on the development of drug eluting stents to treat coronary artery disease.

Calysta Energy (www.calystaenergy.com), Menlo Park, CA., is developing a new biological gas-to-liquids™ (BioGTL™) and biological gas-to-chemicals (BioGTC™) technology using methane - an energy-rich component of natural gas - as a new sustainable biological feedstock for high value industrial chemicals and transportation fuels with cost and performance advantages over current processes. The company is a spinout of DNA2.0, the largest US-based provider of synthetic genes for industrial and academic use.

Gala Therapeutics is a privately held medical device company based in Menlo Park, CA, that is dedicated to developing disease-modifying therapies that improve survival, quality of life, and outcomes for patients with pulmonary diseases.

The Riekes Center is a nonprofit organization that helps students achieve goals in fitness, arts and nature. #gym #musiclessons #natureprograms

GOQii is headquartered in California with offices in Mumbai and Shenzhen. It is dedicated to enabling a permanent shift to a healthier lifestyle with the combination of advanced wearable technology, the world's leading experts, coaches and karma. GOQii focuses on sustained engagement & goal reinforcement and offers a complete ecosystem as a single integrated solution, which is a powerful combination of technology and human connection. GOQii is a collaboration of some of the world's leading experts and an amazing management team who are driven by a passion for healthy sustainable living, and who believe that all of us contain boundless potential. GOQii's goal is to enable millions of people across the world to "be the force" by helping them unleash their untapped potential.

Physical therapy is powerful-for developing strength, managing emerging conditions, or recovering from surgery. But it's challenging for physical therapy to make a significant clinical impact because therapists and patients are worn out. Traditional physical therapy leaves more than 50% of therapists suffering from work-related pain and 70% of patients failing to complete their course of care. On both sides of the therapy table, people need better support. At Luna, they're designing a practice that gives therapists and patients the independence, control, and motivation they need to feel meaningful relief.

Amava is an internet company that partners with organizations large and small to present an ever-evolving collection of ideas to keep you active and engaged. It enables individuals to look for opportunities to work, volunteer, and learn. The company was founded in 2016 and headquartered in San Mateo, California.